Exploitation of Marine Molecules to Manage Alzheimer's Disease

Mar Drugs. 2021 Jun 28;19(7):373. doi: 10.3390/md19070373.

Abstract

Neurodegenerative diseases are sociosanitary challenges of today, as a result of increased average life expectancy, with Alzheimer's disease being one of the most prevalent. This pathology is characterized by brain impairment linked to a neurodegenerative process culminating in cognitive decline and behavioral disorders. Though the etiology of this pathology is still unknown, it is usually associated with the appearance of senile plaques and neurofibrillary tangles. The most used prophylaxis relies on anticholinesterase drugs and NMDA receptor antagonists, whose main action is to relieve symptoms and not to treat or prevent the disease. Currently, the scientific community is gathering efforts to disclose new natural compounds effective against Alzheimer's disease and other neurodegenerative pathologies. Marine natural products have been shown to be promising candidates, and some have been proven to exert a high neuroprotection effect, constituting a large reservoir of potential drugs and nutraceutical agents. The present article attempts to describe the processes of extraction and isolation of bioactive compounds derived from sponges, algae, marine bacteria, invertebrates, crustaceans, and tunicates as drug candidates against AD, with a focus on the success of pharmacological activity in the process of finding new and effective drug compounds.

Keywords: Alzheimer’s disease; algae; marine drugs; natural products; sponges; yields.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Animals
  • Aquatic Organisms*
  • Biological Products
  • Humans
  • Neuroprotective Agents / therapeutic use*

Substances

  • Biological Products
  • Neuroprotective Agents